Last reviewed · How we verify
NCT06993636
Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
trial in Kawasaki Disease in 60 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Children's Hospital of Fudan University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Kawasaki Disease — all drugs for Kawasaki Disease →
- Coronary Artery Aneurysm — all drugs for Coronary Artery Aneurysm →
- Rivaroxaban — all drugs for Rivaroxaban →
- Anticoagulant Drugs — all drugs for Anticoagulant Drugs →
Sponsor
Children's Hospital of Fudan University
Who can join
Adults 2 to 18, any sex, with Kawasaki Disease or Coronary Artery Aneurysm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after Kawasaki disease who received rivaroxaban treatment. Rivaroxaban plasma concentrations, anti-factor Xa activity levels, and genetic polymorphisms will be measured and analyzed to support the population pharmacokinetic/pharmacodynamic analysis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06993636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kawasaki Disease
Currently open trials in the same condition.
- NCT05643651 — Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease · Phase 4 · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
- NCT07291245 — Kawasaki MATCH Trial · NA · recruiting
- NCT06978439 — Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease · Phase 4 · recruiting
- NCT06305611 — European and North Indian Cohort of KaWasaki dIsease · recruiting
Other Children's Hospital of Fudan University trials
Trials by the same sponsor.
- NCT04955821 — Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS · not yet recruiting
- NCT05862688 — A Cohort Study on Anti-microbial Stewardship in PICU · not yet recruiting
- NCT05595239 — Blood Purification in Septic Children · NA · not yet recruiting
- NCT07325903 — Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty · EARLY_PHASE1 · not yet recruiting
- NCT07141615 — Clinical Observation of Qingwei Huazhuo Decoction (Product: Jinsaiyu) in Improving Children With Precocious Puberty of P · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06993636 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Fudan University
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06993636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing